Inflammatory bowel disease — Crohn's disease and ulcerative colitis — has substantial bidirectional comorbidity with depression and anxiety. Up to 30% of IBD patients meet criteria for depression and anxiety, with elevated rates during disease flares and ongoing burden during remission. The relationship is bidirectional: IBD inflammation drives mood symptoms through cytokine, HPA, and microbiome pathways; depression and chronic stress modulate IBD course through inflammation and behavioral pathways. The longevity-psychiatry frame engages IBD-mental health comorbidity through integrated care that addresses both conditions as interrelated.
The biological connections are substantial. IBD-associated inflammation elevates pro-inflammatory cytokines (IL-6, TNF-alpha, CRP) that drive depression biology through the inflammation pathway. HPA axis dysregulation is common in IBD and contributes to both psychiatric symptoms and disease activity. Microbiome alterations in IBD overlap with depression-associated microbiome patterns. Chronic illness burden, fatigue, pain, and quality-of-life impact contribute to mood symptoms through experience as well as biology. The bidirectional pathways mean that addressing one condition typically benefits the other.
The psychiatric medication considerations. SSRIs and SNRIs are generally well-tolerated in IBD patients but may exacerbate GI symptoms in some — start low, titrate gradually. Mirtazapine may be useful for IBD patients with weight loss, poor appetite, and insomnia. Bupropion is reasonable for IBD patients without GI side-effect intolerance. Anticholinergic medications (TCAs, others) may worsen IBD symptoms in some patients due to motility effects. The clinical conversation includes the GI side-effect profile in medication selection.
The IBD-targeted treatments have psychiatric implications. Biologics (anti-TNF agents — infliximab, adalimumab; anti-integrins; JAK inhibitors) may have direct antidepressant effects in patients with IBD and depression, consistent with the inflammation-depression biology. Steroid courses for IBD flares can precipitate psychiatric symptoms (mood lability, psychosis, depression) requiring monitoring. Some IBD medications have neuropsychiatric side effects warranting awareness.
The integrated care model produces better outcomes. Psychiatry-gastroenterology coordination, with explicit attention to bidirectional effects, produces better outcomes than parallel siloed care. Behavioral interventions — stress management, cognitive-behavioral therapy specifically for chronic illness adjustment, mindfulness-based interventions — have evidence in both IBD and comorbid psychiatric conditions. Lifestyle interventions — sleep, exercise, dietary attention (with IBD-specific considerations), social support — affect both. The longevity-psychiatry frame engages IBD patients with attention to both the GI disease and the broader cognitive and psychiatric trajectory. The discipline is to recognize IBD-mental health comorbidity as integrated biology requiring integrated care, coordinate with gastroenterology, choose medications and interventions that respect both domains, and engage the broader lifestyle work that benefits both.